☆ 4.6 Article

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders

Malgorzata Mikulska et al.

Summary: The outcome of early treatment with antivirals or monoclonal antibodies for COVID-19 in patients with haematological malignancies is uncertain. A retrospective study was conducted to assess the efficacy of these treatments in mild/moderate cases between March 2021 and July 2022. Among the 328 patients included, treatment failure occurred in 9.5% of cases and was associated with older age, fewer vaccine doses, and monoclonal antibody therapy. The mortality rate in patients who developed severe COVID-19 despite early treatment was 26%.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Livio Pagano et al.

BLOOD (2022)

Add to Collection

Article Hematology

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have impaired antibody response to COVID-19 vaccination. A third dose of the vaccine can improve the antibody response in some CLL patients. Patients on active treatment and those recently treated with anti-CD20 therapy have lower antibody response rates.

BLOOD (2022)

Add to Collection

Editorial Material Hematology

COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion

Clare Sun

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity

Yandong Shen et al.

Summary: Chronic lymphocytic leukaemia (CLL) and monoclonal B-cell lymphocytosis (MBL) patients have poor immune response to COVID-19 vaccines, with most of them failing to produce sufficient antibody levels. The patients' treatment status and reduced immune function are associated with vaccine immunization failure.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Editorial Material Hematology

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Cristina Bagacean et al.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

J. Erika Haydu et al.

Summary: This prospective study demonstrates that SARS-CoV-2 vaccination induces functional T-cell and antibody responses in patients with CLL. The serologic response to the vaccine is more common in treatment-naive patients. Most patients had functional spike-specific T-cell responses in interferon-gamma release assays.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Carsten U. Niemann et al.

Summary: "Previous studies have shown high mortality rates in patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19). Although the Omicron variant is considered to have a milder disease course in the general population, the outcome for immunocompromised patients has not been reported previously. A study found that hospitalization and intensive care unit admission rates significantly declined in CLL patients during the period when the Omicron sublineage BA.2 variant dominated, but the 30-day mortality remained high. However, for a larger population-based cohort of CLL patients, including those in hospitals, the 30-day mortality was 2%. Therefore, close monitoring and preemptive antiviral therapy should be considered for CLL patients with close hospital contacts, especially those >70 years old with comorbidities, upon a positive SARS-CoV-2 test."

BLOOD (2022)

Add to Collection

Letter Oncology

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Yotam Bronstein et al.

CANCER CELL (2022)

Add to Collection

Letter Oncology

COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia

Helen Parry et al.

CANCER CELL (2022)

Add to Collection

Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

Jose Luis Pinana et al.

Summary: This study found that lack of detectable antibodies at 3-6 weeks after full vaccination was the main variable associated with breakthrough infection, and antibody titers above 250 BAU/mL significantly reduced the incidence and severity of the infection.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

Tommy Nyberg et al.

Summary: The Omicron variant shows lower severity compared to Delta, especially in terms of hospital admission and death, with significant variations by age. Unvaccinated cases experience a larger reduction in intrinsic severity, while vaccinated cases experience reduced vaccine effectiveness. Booster vaccination with mRNA vaccines provides over 70% protection against hospitalization and death in breakthrough Omicron infections.

LANCET (2022)

Add to Collection

Article Virology

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19

Joe B. Harford et al.

Summary: SGT-53 is a novel investigational agent that carries a plasmid vector driving expression of the human TP53 gene. It is currently being tested in phase II trials for advanced pancreatic cancer. Studies have shown that p53, besides being a tumor suppressor, also plays a role in immune responses. Various viruses manipulate p53-dependent pathways to counteract the antiviral activities of the host immune system. Transfection of cells with SGT-53 can produce exogenous active p53 protein, making it a potential therapy for infections including COVID-19.

VIRUSES-BASEL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Aekkachai Tuekprakhon et al.

Summary: The Omicron variant of SARS-CoV-2 has rapidly spread globally and has evolved into different sublineages, with BA.4 and BA.5 dominating in South Africa. These sublineages show reduced neutralization by vaccine and naturally immune serum, indicating the possibility of repeat Omicron infections.

CELL (2022)

Add to Collection

News Item Multidisciplinary Sciences

WHAT THE LATEST OMICRON SUBVARIANTS MEAN FOR THE PANDEMIC

Ewen Callaway

NATURE (2022)

Add to Collection

Letter Medicine, General & Internal

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

Nicole P. Hachmann et al.

Summary: A small study found that omicron subvariants BA.2.12.1, BA.4, and BA.5 of SARS-CoV-2 were more likely to evade neutralizing antibodies induced by both vaccination and previous infection compared to the prior omicron subvariants BA.1 and BA.2.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study

Isobel L. Ward et al.

Summary: Based on a retrospective cohort study conducted in England from December 1, 2021 to December 30, 2021, the risk of covid-19 death was found to be reduced by 66% for omicron BA.1 compared to delta. The reduction in risk was more pronounced in the 18-59 year age group.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Article Oncology

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Maria Stefania Infante et al.

Summary: Patients with lymphoproliferative diseases treated with targeted drugs have increased severity and mortality from COVID-19. Age, active malignancy, severe COVID-19, and ICU admission are risk factors for mortality. Vaccination can reduce overall mortality rate.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

Francesca Romana Mauro et al.

Summary: Pneumococcal vaccination response was analyzed in 112 CLL patients, with factors like age, IgG levels, prior treatment, and disease progression being associated with lower immune response rates. Age ≥ 60 years, IgG levels < 400 mg/L, prior treatment, and signs of disease progression were linked to a decreased response rate.

LEUKEMIA (2021)

Add to Collection

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Thomas Chatzikonstantinou et al.

Summary: Patients with CLL are more susceptible to the impact of COVID-19, with age, CLL-directed treatment, and cardiac failure being significant risk factors for outcomes. Untreated patients have a better chance of survival, and age, cardiac failure, and CLL-directed treatment are significant risk factors for OS.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

Add to Collection

Article Hematology

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Lindsey E. Roeker et al.

BLOOD (2021)

Add to Collection

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Hematology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato et al.

BLOOD (2020)

Add to Collection

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Article Oncology

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfo et al.

LEUKEMIA (2020)

Add to Collection

Letter Oncology

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Moritz Fuerstenau et al.

LEUKEMIA (2020)

Add to Collection

Letter Oncology

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2020)

Add to Collection

Review Hematology

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abi Vijenthira et al.

BLOOD (2020)

Add to Collection

Article Hematology

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek et al.

BLOOD (2018)

Add to Collection

Letter Hematology

Ibrutinib may impair serological responses to influenza vaccination

Abby P. Douglas et al.

HAEMATOLOGICA (2017)

Add to Collection

Letter Hematology

Ibrutinib may impair serological responses to influenza vaccination

Abby P. Douglas et al.

HAEMATOLOGICA (2017)

Add to Collection

Letter Oncology

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Clare Sun et al.

JAMA ONCOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence

A Takaoka et al.

NATURE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.